Director at $MTRN sells 2,446 shares in insider sale

A recent SEC filing revealed that VINOD M KHILNANI, serving as a director at $MTRN, divested 2,446 company shares on 02-17-2026, raking in an estimated $363,637. This sale represented about 13.8% of their holdings in this stock class, leaving them with 15,219 shares of $MTRN stock in their possession.

Over the past half-year, $MTRN insiders have engaged in three instances of trading the company’s stock. Notably, all three actions involved selling shares, with no purchases recorded during this period. VINOD M KHILNANI made the bulk of these transactions, offloading 4,000 shares for an approximate sum of $595,456, while GREGORY R. CHEMNITZ, Vice President, General Counsel, and Secretary, also participated by selling 864 shares for around $97,827.

Institutional investors have shown varying degrees of interest in $MTRN stock recently. Out of 118 firms, 182 reduced their existing holdings in the latest quarter. Key movements in the market include AMERICAN CENTURY COMPANIES INC adding 156,164 shares (a 42.8% increase) to their portfolio, valued at approximately $19,414,308. Conversely, UBS AM, a DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC, purged 136,038 shares (a 76.3% decline) from their holdings, representing around $16,912,244.

Turning to financial performance, $MTRN showcased revenue figures of $489.8M in Q4 2025, marking an uptick of 12.1% compared to the corresponding period in the previous year. Investors keen on tracking the company’s financials can do so through Quiver Quantitative’s dedicated page on $MTRN stock.

Analysts monitoring $MTRN over recent months have issued favorable buy ratings. Among the analysts weighing in on the stock, 1 firm provided a positive “Overweight” rating on 01/14/2026. For individuals interested in following analyst ratings and price targets for $MTRN, Quiver Quantitative’s $MTRN forecast page offers valuable insights.

It is important to note that this article is intended for informational purposes only and should not be considered financial advice. Readers are encouraged to refer to Quiver Quantitative’s disclaimers for further details and guidance.